Friday, February 17
Click here to email Meeting Organizers.
| Time (EST) | Session | Topic | Presenter |
|---|---|---|---|
|
9:00-9:10 |
Opening | Welcome | COL Julie Ake, MHRP |
|
9:10–10:45 Moderator: |
Immunologic Analyses (RV144 Follow-up trials) |
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response (RV305) |
LaTonya Williams, Duke |
| Sensing of ALVAC by innate cells in RV306 |
Dominic Paquin-Proulx, MHRP |
||
| Determinants of Durability in RV306 |
Shelly Krebs and Rasmi Thomas, MHRP |
||
| RV546: Late boost of A244 and IHV01 with or without ALFQ and Fractional Dosing |
Jittima Dhitavat, Mahidol VTC |
||
| Exploratory innate and mucosal research in RV546 – Preliminary Data |
Alexandra Schuetz, AFRIMS |
||
| 10:45-11:05 | Break | ||
|
11:05-11:50 Moderator:
|
Immunologic Analyses (ALF)
|
RV460: Can ALF adjuvant enhance the responses of DNA priming? | Josphat Kosgei, HJFMRI Kenya |
| Co-administration of liposomal adjuvant ALF43 along with DNA vaccination improves binding responses against HIV-1 | Elisavet Serti Chrisos, MHRP | ||
| ALFQ induces potent cellular immune responses | Mangala Rao, MHRP | ||
|
11:50-12:50 Moderator: |
Ongoing / Planned Clinical Trials for HIV Prevention |
RV575: ALFQ Dose Optimization |
MAJ Paul Adjei, MHRP |
| RapidVax/ RV591: Rapid dose‑escalation of CH505 TF chTrimer+ALFQ and Ad26.Mos4.HIV to mimic acute HIV replication |
Grace Mirembe, MUWRP |
||
| RV584: Novel Long-Acting Bispecific Antibody in People with HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis |
Nyanda Ntinginya, MMRC |
||
| Clinical Trial of Combined Long Term Efferocytosis and ADCC Responses (CLEAR) |
Frank Maldarelli, NCI |
||
| 12:50–1:40 | Lunch | ||
|
1:40–2:40 Moderator: |
Novel HIV Antigens
|
Structural Mosaic mRNA HIV Vaccine Study in Rhesus Macaques | Matt Parsons, AFRIMS |
| Germline Targeting Immunogen for Induction of CD4 mimicking CD4BS bnAb precursors in monkeys | Bart Haynes, Duke | ||
| HIV-1 acute infection multiple founder variants as vaccine candidates |
Morgane Rolland, MHRP |
||
| 2:40–3:00 | Break | ||
|
3:00–3:45 Moderator:
|
Future HIV Vaccine Development |
||
| PANEL DISCUSSION |
Merlin Robb, HJF |
||
| Closing Remarks | Mary Marovich, DAIDS | ||
During the MHRP Vaccine Science Meeting, unpublished data may be presented and must be treated as confidential. Permission from presenting author(s) must be obtained before communicating results or relevant discussion to outside parties.